SCHEMBL438008

SCHEMBL438008

[CH2-][NH2+]Cc1ccc(C)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 3/20 0.46
CYP1A2 P05177 1/20 0.42
CYP2A6 P11509 1/20 0.42
TAAR1 Q96RJ0 1/20 0.42
ACHE P22303 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
AGXT P21549 2/20 0.41
MAPT P10636 2/20 0.35
CHRM2 P08172 1/20 0.35
TP53 P04637 1/20 0.35
ALDH1A1 P00352 2/20 0.34
POLB P06746 2/20 0.34
HRH3 Q9Y5N1 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA9 Q16790 1/20 0.34
LMNA P02545 1/20 0.34
KCNH2 Q12809 1/20 0.34
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13389323 0.79 TP53 (0.43) CYP2A6TAAR1TDP1TP53ALDH1A1
SCHEMBL436889 0.75 CYP1A2 (0.50) IDO1CYP1A2CYP2A6TAAR1ACHE
SCHEMBL13389464 0.75 LPL (0.45) MAPTALDH1A1POLBCA2KDM4E
SCHEMBL10250538 0.74 IDO1 (0.46) IDO1CYP1A2CYP2A6TAAR1AGXT
SCHEMBL13389477 0.74 ESR1 (0.50) IDO1TAAR1TDP1MAPTALDH1A1
SCHEMBL436783 0.74 IDO1 (0.46) IDO1TAAR1AGXTCHRM2LMNA
SCHEMBL438568 0.73 TSHR (0.42) ACHETP53CA1CA2LMNA
SCHEMBL13389468 0.73 PTGS1 (0.42) MAPTALDH1A1POLBLMNAMEN1
SCHEMBL13325730 0.73 ALDH1A1 (0.56) TDP1MAPTTP53ALDH1A1MEN1
SCHEMBL438658 0.73 IDO1 (0.52) IDO1CYP1A2TAAR1AGXTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022056042-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2022-03-17 WO disclosed
EP-3512556-B1 COMBINED TREATMENT WITH A TLR7 AGONIST AND AN HBV CAPSID ASSEMBLY INHIBITOR HOFFMANN LA ROCHE (CH) 2021-08-18 EP disclosed
WO-2020231333-A1 TYROSINASE INHIBITORS AND THEIR USES NATIONAL UNIVERSITY OF SINGAPORE (SG) 2020-11-19 WO disclosed
US-10035799-B2 COMT inhibiting methods and compositions LIEBER INSTITUTE FOR BRAIN DEVELOPMENT (US) 2018-07-31 US disclosed
US-20160222011-A1 COMT Inhibiting Methods and Compositions LIEBER INSTITUTE, INC. 2016-08-04 US disclosed
US-9144573-B2 Prostaglandin transporter inhibitors ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2015-09-29 US disclosed
US-20150073136-A1 PYRAZINONE DERIVATIVES ASTRAZENECA AB (SE) 2015-03-12 US disclosed
US-8889692-B2 Pyrazinone derivatives, pharmaceutically acceptance salts thereof and their uses ASTRAZENECA AB (SE) 2014-11-18 US disclosed
US-8772327-B2 Phenylpropionic acid derivative and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2014-07-08 US disclosed
EP-2684881-A1 COMPOUND HAVING FLUORESCENT CHROMOPHORE, ION CONCENTRATION SENSOR INCLUDING COMPOUND, REAGENT INCLUDING COMPOUND, REAGENT KIT PROVIDED WITH REAGENT, PRECURSOR OF COMPOUND, AND METHOD FOR SYNTHESIZING COMPOUND National University Corporation Hokkaido University (JP) 2014-01-15 EP disclosed
US-7771962-B2 CD10-activated prodrug compounds MEDAREX, INC. (US) 2010-08-10 US disclosed
US-20090270647-A1 METHOD FOR PRODUCING ALPHA - AMINO ACID INCLUDING PHOSPHORUS AND PRODUCTION INTERMEDIATES THEREOF MEIJI SEIKA KAISHA LTD. (JP) 2009-10-29 US disclosed
US-20090215712-A1 PYRAZOLE DERIVATIVES PFIZER INC 2009-08-27 US disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 US disclosed
US-20090136980-A1 CD10-activated prodrug compounds MEDAREX, INC. (US) 2009-05-28 US disclosed
US-20090110753-A1 Enzyme-cleavable prodrug compounds MEDAREX, INC. (US) 2009-04-30 US disclosed
US-7435728-B2 Pyrazole derivatives PFIZER INC (US) 2008-10-14 US disclosed
US-7425541-B2 Enzyme-cleavable prodrug compounds MEDAREX, INC. (US) 2008-09-16 US disclosed
US-20070275903-A1 Tripeptide prodrug compounds MEDAREX, INC. (US) 2007-11-29 US disclosed
US-7214663-B2 Tripeptide prodrug compounds MEDAREX, INC. (US) 2007-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215712-A1 PYRAZOLE DERIVATIVES RRM2B, REV1, RRM2 IDO1 578/4885CYP1A2 348/4885CYP2A6 1296/4885
US-20090270647-A1 METHOD FOR PRODUCING ALPHA - AMINO ACID INCLUDING PHOSPHORUS AND PRODUCTION INTERMEDIATES THEREOF BCAT1, BCAT2, DAO IDO1 615/4885CYP1A2 426/4885CYP2A6 177/4885
US-10035799-B2 COMT inhibiting methods and compositions COMT, SLC6A3, MAOA IDO1 875/4885CYP1A2 157/4885CYP2A6 144/4885
US-20160222011-A1 COMT Inhibiting Methods and Compositions COMT, SLC6A3, MAOA IDO1 875/4885CYP1A2 157/4885CYP2A6 144/4885
US-20090143358-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 IDO1 2615/4885CYP1A2 2489/4885CYP2A6 1907/4885
US-20150073136-A1 PYRAZINONE DERIVATIVES CYP3A7, CYP3A4, CYP2D6 IDO1 1812/4885CYP1A2 9/4885CYP2A6 115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.